Viking Therapeutics, Inc. Earnings

Viking Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Viking Therapeutics, Inc.’s net profit fell -66.8% since last year same period to $-45.63Mn in the Q1 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated -28.83% fall in its net profits since last 3-months.

Viking Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2025. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a -11.18% fall from last quarter’s estimates.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.31.

Viking Therapeutics, Inc.’s earning per share (EPS) fell -57.69% since last year same period to -0.41 in the Q1 2025. This indicates that the Viking Therapeutics, Inc. has generated -57.69% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Viking Therapeutics, Inc.’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Viking Therapeutics, Inc.’s return on equity (ROE) stands at -0.14.